Two Doses of Fosaprepitant Included Prophylactic Treatment for the Three-day Cisplatin-based Chemotherapy Induced Nausea and Vomiting

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2024 Jun 5

PMID 38836908

Authors

Yanying Li

Yuming Wan

Xiaoyun Yang

Ping Chen

Yan Gui

Lang He

Yingwei Xie

Jing Tian

Ping Duan

Guangguo Liu

Yu Sun

Jiang Zhu

Affiliations

Soon will be listed here.

Abstract

Purpose: Neurokinin 1 receptor antagonists included prophylactic treatment was recommended for patients who receive one-day cisplatin chemotherapy. It is unclear whether the prolonged administration of fosaprepitant is effective for three-day cisplatin-based chemotherapy induced nausea and vomiting (CINV). We aim to explore the prophylactic antiemetic efficacy and safety of two doses of fosaprepitant included regimen in the patients receiving multiple-day cisplatin chemotherapy.

Methods: This randomized, parallel-group, open-labelled study was conducted in nine hospitals between February 2021 and February 2023. Patients diagnosed as lung cancer and chemotherapy naive were screened. Eligible participants were scheduled to be treated with highly emetogenic chemotherapy regimen which including three days of cisplatin. Then they were randomly divided into the experimental group (two doses of fosaprepitant, Group 2DF) and the control group (one dose of fosaprepitant, Group C). The primary endpoints included the safety and the average none CINV days (NCDs). This study was registered on the website of chictr.org.cn, number ChiCTR2100042665.

Results: Overall, 204 participants were randomly assigned, and 198 patients were analyzed. No statistical difference in adverse events was found between the two groups. All treatment-related adverse effects for fosaprepitant observed were of grade 1-2. The average NCDs of Group 2DF was significantly more than Group C (18.21 ± 3.40 days vs 16.14 ± 5.20 days, P = 0.001). Furthermore, the better life function score was achieved in Group 2DF according to FLIE questionnaire.

Conclusion: The administration of two-dose fosaprepitant was safe and more effective than one dose in protecting patients from CINV induced by three-day cisplatin included chemotherapy.

References

Abdel-Malek R, Abbas N, Shohdy K, Ismail M, Fawzy R, Salem D . Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy. J Egypt Natl Canc Inst. 2017; 29(3):155-158. DOI: 10.1016/j.jnci.2017.05.001. View

Wu F, Lin X, Yang Z, Sun Z, Zeng F, Heng J . Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer. Clin Lung Cancer. 2018; 19(6):e913-e918. DOI: 10.1016/j.cllc.2018.08.006. View

Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K . Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. J Clin Oncol. 2021; 40(2):180-188. PMC: 8718175. DOI: 10.1200/JCO.21.01315. View

Kamiya T, Sakurai M, Kikuchi T, Okayama M, Mizuno K, Tanigawa T . Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma. Hematology. 2021; 26(1):945-949. DOI: 10.1080/16078454.2021.2001150. View

Albany C, Brames M, Fausel C, Johnson C, Picus J, Einhorn L . Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day.... J Clin Oncol. 2012; 30(32):3998-4003. DOI: 10.1200/JCO.2011.39.5558. View

Zhao Y, Yang Y, Gao F, Hu C, Zhong D, Lu M . A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). EClinicalMedicine. 2023; 55:101771. PMC: 9874334. DOI: 10.1016/j.eclinm.2022.101771. View

Kondagunta G, Motzer R . Chemotherapy for advanced germ cell tumors. J Clin Oncol. 2006; 24(35):5493-502. DOI: 10.1200/JCO.2006.08.7882. View

Jordan K, Chan A, Gralla R, Jahn F, Rapoport B, Warr D . 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer. 2016; 25(1):271-275. DOI: 10.1007/s00520-016-3332-x. View

Yang L, Sun X, Qin S, Cheng Y, Shi J, Chen Z . Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study. Eur J Cancer Care (Engl). 2017; 26(6). PMC: 5697660. DOI: 10.1111/ecc.12668. View

10.

Ranganath P, Einhorn L, Albany C . Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy. Biomed Res Int. 2015; 2015:943618. PMC: 4573879. DOI: 10.1155/2015/943618. View

11.

Schwartzberg L, McLaughlin T, Geller R, Gabrail N, Marks S . Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy. J Comp Eff Res. 2018; 7(12):1161-1170. DOI: 10.2217/cer-2018-0089. View

12.

Zhang J, Lin M, Jin Y, Gu L, Li T, Yuan B . Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia. Breast Cancer Res Treat. 2020; 182(3):719-726. DOI: 10.1007/s10549-020-05730-2. View

13.

Furugaki K, Yoshida J, Ogawa R, Nagamatsu I, Miura M, Hokazono K . [Chemotherapy for non-small cell lung cancer: split-dose administration of Cisplatin over four consecutive days and Vinorelbine ditartrate]. Gan To Kagaku Ryoho. 2009; 36(2):259-63. View

14.

Gao A, Guan S, Sun Y, Wang L, Meng F, Liu X . Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy. BMC Cancer. 2023; 23(1):609. PMC: 10314477. DOI: 10.1186/s12885-023-11070-3. View

15.

Olver I, Grimison P, Chatfield M, Stockler M, Toner G, Gebski V . Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer. 2013; 21(6):1561-8. DOI: 10.1007/s00520-012-1696-0. View

16.

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice J . Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011; 29(11):1495-501. DOI: 10.1200/JCO.2010.31.7859. View

17.

Sun Y, Zheng Y, Yang X, Xie K, Du C, He L . Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China. J Cancer Res Clin Oncol. 2021; 147(9):2701-2708. DOI: 10.1007/s00432-021-03554-1. View

18.

Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T . Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 21(2):242-249. DOI: 10.1016/S1470-2045(19)30678-3. View

19.

Rosell R, Karachaliou N . Lung cancer in 2014: optimizing lung cancer treatment approaches. Nat Rev Clin Oncol. 2014; 12(2):75-6. DOI: 10.1038/nrclinonc.2014.225. View

20.

Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D . A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients.... Ann Oncol. 2017; 29(2):452-458. PMC: 5834144. DOI: 10.1093/annonc/mdx698. View